Mirati therapeutics, inc. (MRTX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-258,999

-213,256

-169,152

-142,447

-124,621

-98,418

-88,041

-76,823

-67,293

-70,430

-72,257

-75,328

-79,050

-83,118

-81,813

-81,133

-74,518

-64,544

-56,514

-46,390

-41,982

-43,698

-44,544

-65,324

-62,298

-52,859

0

0

0

Non-cash adjustments reconciling net loss to operating cash flows:
Depreciation

256

200

275

195

178

175

146

173

180

184

179

170

167

180

198

213

226

212

198

183

165

199

220

223

227

171

0

0

0

Accretion of discount on investments

3,024

3,421

3,381

2,908

2,075

1,320

791

464

357

266

231

196

78

-7

-663

-613

-450

-337

415

472

466

534

439

313

167

0

0

0

0

Share-based compensation expense

65,973

55,537

43,088

32,040

23,325

15,854

12,910

10,331

8,680

6,786

8,006

9,287

9,352

10,624

10,428

10,472

10,976

10,254

10,140

9,927

8,420

7,050

5,548

3,809

2,307

1,823

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,517

7,734

30,237

29,645

19,799

0

0

0

Change in restructuring costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

13

13

0

0

0

0

Lease incentive liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Changes in operating assets and liabilities:
Other current assets

4,059

5,487

6,951

6,771

978

-1,052

-80

-155

3,611

3,409

2,369

3,149

-115

-254

-521

-290

-934

-279

387

272

504

1,209

96

-592

492

-340

0

0

0

Other long-term assets

3,477

4,375

4,028

4,157

1,563

359

-1,797

-1,817

-2,871

-3,606

-1,480

-741

549

1,259

0

0

0

-

-

-

-

326

0

0

0

-

-

-

-

Accounts payable, accrued liabilities, deferred revenue and other liabilities

31,007

23,027

13,605

10,132

9,104

12,920

10,801

6,825

5,108

-1,177

-1,871

-1,795

746

5,295

3,800

6,606

5,861

4,370

4,444

1,239

973

151

-1,240

1,337

-1,839

-68

0

0

0

Cash flows used in operating activities

-172,248

-147,726

-126,619

-113,917

-96,630

-70,096

-63,067

-57,986

-54,422

-64,706

-67,063

-70,270

-69,297

-68,017

-67,924

-65,496

-57,891

-50,714

-43,271

-37,018

-33,725

-32,748

-31,873

-27,451

-30,913

-29,455

0

0

0

Investing activities:
Purchases of short-term investments

633,154

530,228

558,135

317,125

280,433

255,795

161,230

165,470

140,068

100,558

98,111

107,013

111,782

70,269

131,191

113,610

90,772

104,954

42,524

45,551

42,024

10,468

51,651

51,958

56,810

68,408

0

0

0

Security deposit, restricted cash equivalents and marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Sales and maturities of short-term investments

371,771

355,640

325,557

241,260

184,660

110,152

90,229

79,442

87,630

91,988

97,273

105,980

109,290

108,720

106,185

92,328

71,180

54,530

46,760

38,460

32,910

35,073

25,844

23,276

30,084

39,138

0

0

0

Purchases of property, plant, and equipment

1,776

1,552

0

0

0

-

-

-

-

-

-

-

-

196

96

77

356

329

362

419

402

386

328

312

116

204

0

0

0

Cash flows used in investing activities

-263,159

-176,140

-232,884

-76,056

-95,895

-145,765

-71,038

-86,029

-52,519

-8,651

-1,051

-1,264

-2,643

38,255

-25,102

-21,359

-19,948

-50,753

3,874

-7,510

-9,516

24,219

-26,099

-28,967

-26,782

-29,470

0

0

0

Financing activities:
Proceeds from issuance of common stock, net of issuance costs

543,924

327,830

327,810

327,813

238,546

130,663

217,377

217,374

86,714

153,530

66,816

66,816

66,816

0

4

94,932

94,932

143,293

143,289

48,361

48,361

0

0

0

0

-

-

-

-

Proceeds from issuances under employee stock purchase plan

-

-

-

-

-

442

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options and warrants

20,973

8,473

5,594

6,676

6,557

9,747

12,379

12,374

10,893

5,003

2,149

0

29

2,355

2,435

2,577

2,633

552

823

781

870

887

1,075

997

823

561

0

0

0

Proceeds from disgorgement of shareholders' short-swing profits

41

1,050

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows provided by financing activities

565,628

338,028

335,017

336,102

246,563

140,852

230,031

230,023

97,751

158,677

69,096

66,947

67,142

2,652

2,947

98,018

98,087

144,367

144,363

49,392

49,231

887

55,271

55,193

55,019

54,757

0

0

0

Increase in cash, cash equivalents and restricted cash

130,221

14,162

-24,486

146,129

54,038

-75,009

95,926

86,008

-9,190

85,320

982

-4,587

-4,798

-27,110

-90,079

11,163

20,248

42,900

104,966

4,864

5,990

-7,642

-2,701

-1,225

-2,676

-4,168

0

0

0

Supplemental disclosures of non-cash investing activities:
Purchases of property, plant, and equipment included within accounts payable and accrued liabilities

0

-

-

-

0

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

0

0

0

-

-

-

-